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Adverse effects of hyperphosphatemia on myocardial hypertro-
phy, renal function, and bone in rats with renal failure.
Background. Hyperphosphatemia and disturbances in cal-
cium or parathyroid hormone (PTH) metabolism contribute to
the high incidence of cardiovascular disease and renal osteodys-
trophy in chronic renal failure (CRF). We evaluated the effect
of hyperphosphatemia on the cardiovascular system, on renal
function, and on bone in experimental uremia.
Methods. Wistar rats were submitted to parathyroidectomy
(PTx) and 5/6 nephrectomy (Nx) with minipump implan-
tation, delivering 1-34 rat PTH (physiologic rate), or were
sham-operated and received vehicle. Only phosphorus content
(low-phosphorus (LP) 0.2%; high-phosphorus (HP) 1.2%) dif-
ferentiated diets. We divided the groups as follows: PTx +Nx
+LP; sham + LP; PTx + Nx + HP; and sham + HP. Tail-cuff
pressure and weight were measured weekly. After 2 months,
biochemical, arterial, and myocardial histology and bone histo-
morphometry were analyzed.
Results. Heart weight normalized to body weight (heart
weight/100 g body weight) was higher in PTx + Nx + HP rats
(PTx + Nx + HP = 0.36 ± 0.01 vs. sham + HP = 0.29 ± 0.01, PTx
+ Nx + LP = 0.32 ± 0.01, sham + LP = 0.28 ± 0.01) (P < 0.05).
Serum creatinine levels were higher in PTx + Nx + HP rats
than in PTx + Nx + LP rats (1.09 ± 0.13 vs. 0.59 ± 0.03 mg/dL)
(P < 0.05). Levels of PTH did not differ significantly between
the groups. Myocardial and arterial histology detected no vas-
cular calcification or fibrosis. Bone histomorphometry revealed
an association, unrelated to uremia, between HP diets and de-
creased trabecular connectivity.
Conclusion. Myocardial hypertrophy, impaired renal func-
tion, and adverse effects on bone remodeling were associated
with hyperphosphatemia and were not corrected by PTH re-
placement. Although no vascular calcification was observed
in this model, we cannot rule out an adverse effect of hyper-
phosphatemia on the vascular bed. Our finding underscores the
importance of phosphorus control in reducing morbidity and
mortality in CRF patients.
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Controlling phosphorus retention has long been recog-
nized as a key component in the clinical management of
patients with chronic renal failure (CRF) [1]. In advanced
CRF, renal phosphorus excretion is insufficient to remove
the amount of dietary phosphorus that is absorbed daily.
In addition, dialysis treatment does not correct phospho-
rus serum levels. As a consequence, hyperphosphatemia
is commonly found in CRF patients, especially in those on
dialysis [2]. The importance of managing phosphorus re-
tention has been emphasized due to its role in the patho-
genesis of secondary hyperparathyroidism (SHPT) [3].
However, disturbances in phosphorus metabolism have
other significant adverse consequences [4]. Hyperphos-
phatemia may hasten the progression of renal disease [5],
and recent studies have implicated hyperphosphatemia,
either alone or in combination with the measures cur-
rently used to control it, in the substantially higher inci-
dence of cardiovascular mortality, as well as of visceral
and peripheral vascular calcification, seen in advanced
CRF patients [2]. Cardiovascular disease is extremely
common and accounts for at least 50% of deaths among
this population [6, 7]. The exact mechanism whereby
hyperphosphatemia contributes to excess mortality is un-
known, but vascular calcification may be involved. Phos-
phorus probably induces calcification not only through
indirect mechanisms but also by direct action at specific
tissue sites. An in vitro study by Jono et al [8] showed
that inorganic phosphate was able to transform vascu-
lar smooth muscle cells into calcifying cells by a di-
rect mechanism involving the phosphate cotransporter
Pit-1. This leads to the local formation of calcium- and
phosphate-containing apatite crystals by cells that do not
normally favor the deposition of such crystals. Hyper-
phosphatemia may also be indirectly involved through
excessive secretion of parathyroid hormone (PTH) [9].
However, in patient studies, an isolated phosphorus ef-
fect cannot be evaluated because hyperphosphatemia
is typically accompanied by elevated PTH, and ther-
apeutic interventions can facilitate vascular calcifica-
tion, worsen renal function, and adversely affect bone
remodeling.
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We designed an experimental study involving diets with
high phosphorus (HP) content that would induce hyper-
phosphatemia, while taking measures to ensure that PTH
levels remained within the physiologic range. We did so in
order to investigate the isolated effect of phosphorus on
the development of cardiovascular calcification, cardiac
fibrosis, and other cardiovascular changes, as well as the
isolated effect of hyperphosphatemia on renal function
and on bone in chronic experimental uremia.
METHODS
Experimental protocol
A total of 32 male Wistar rats, obtained from our lo-
cal breeding colony, with initial weights of 280 to 330 g,
were used in this study. They were housed in individual
cages in a light-controlled environment (12 hours on/12
hours off) at a constant temperature (25◦C) and humid-
ity (25%). They were divided into four groups. Animals
from group 1 (N = 8) and group 3 (N = 8) were anes-
thetized with pentobarbital (50 mg/kg intraperitoneally)
and then submitted to parathyroidectomy (PTx) involv-
ing microsurgical techniques using electrocautery. The
animals were allowed to recover from surgery for 1 week.
After this period, they were anesthetized as before and,
if their ionized calcium (iCa) was <7.2 mg/dL, they were
submitted to 5/6 nephrectomy (Nx), which consisted of
removal of the right kidney and infarction of approxi-
mately two thirds of the left kidney. Simultaneous to the
Nx procedure, normal PTH activity was restored by sub-
cutaneous implantation of an Alzet Model 2mL4 osmotic
minipump (Alza Corp., Palo Alto, CA, USA), providing
continuous infusion of 1-34 rat PTH [10] (0.022 lg/100
g/hour) (Sigma-Aldrich, St. Louis, MO, USA). On post-
Nx day 28, the same animals were given light ether anes-
thesia and the osmotic minipump was replaced (pump-
ing lifetime of 28 days) with another minipump set to the
same infusion rate. Groups 2 (N = 8) and 4 (N = 8) were
submitted to sham PTx and sham Nx (sham controls), in-
cluding subcutaneous implantation of identical osmotic
minipumps, delivering only vehicle (2% cysteine) (Sigma-
Aldrich). Immediately after Nx, animals were fed iden-
tical diets of rodent chow (Harlan-Teklad, Indianapolis,
IN, USA), with the following exceptions in phosphorus
content: groups 1 [PTx +Nx +low phosphorus (LP)] and
2 (sham + LP) received a LP diet (P = 0.2%); groups 3
(PTx + Nx + HP) and 4 (sham + HP) received a HP diet
(P = 1.2%). All diets were equal in their content of vi-
tamin D, calcium (0.7%), protein (24%), and calories. A
pair-feeding protocol was used. Weight measurement and
tail cuff plethysmography (TCP) were performed weekly.
A fluorochrome bone marker (Terramycin) in a dose of
25 mg/kg was ip injected on days 11 and 12, as well as on
days 4 and 5 before sacrifice. After 8 weeks of treatment,
the animals were anesthetized and sacrificed through aor-
tic puncture exsanguination. Serum samples were frozen
at −20◦C for later biochemical evaluation. Whole blood
was also collected to determine hematocrit. The heart
was excised, blotted, and weighed. We also determined
the heart weight to body weight ratio (heart weight/100 g
body weight). The thoracic aorta and the left femoral
artery were carefully removed and, along with the heart,
fixed in buffered formalin.
All experimental procedures were conducted in accor-
dance with the guidelines of the Standing Committee on
Animal Research of the University of Sa˜o Paulo.
Analytic determination
On the day of Nx surgery, whole blood was collected
by retro-orbital puncture. A model AVL-9140 Autoana-
lyzer (AVL Scientific Corporation, Roswell, GA, USA)
was used to measure iCa levels in this blood either imme-
diately after collection or following sacrifice (in frozen
samples). Serum creatinine was determined by using
a colorimetric assay (modified Heinegard-Tiderstro¨m).
Phosphorus was determined using a colorimetric assay
(Labtest Lagoa Santa, MG, Brazil). A rat PTH IRMA
kit (Immutopics, San Clemente, CA, USA) was used to
measure PTH. Hematocrit was also determined.
Morphologic techniques
Bone histomorphometry. At the end of the experimen-
tal period, the left femur of each rat was removed, dis-
sected free of soft tissue, immersed in 70% ethanol, and
processed as previously described [11]. Using a K Jung mi-
crotome, distal femurs were cut into sections of 5 lm and
10 lm in thickness. The 5 lm sections were stained with
0.1% toluidine blue, pH 6.4, and at least two nonconsecu-
tive sections were examined for each sample. Static, struc-
tural, and dynamic parameters of bone formation and
resorption were measured at the distal metaphyses (mag-
nification, ×250), 195 lm from the epiphyseal growth
plate, in a total of 30 fields, using a semi-automatic im-
age analyzer Osteomeasure (Osteometrics, Inc., Atlanta,
GA, USA). Mineral apposition rate (MAR) was deter-
mined from the distance between the two terramycin
labels, divided by the time interval between the two ter-
ramycin administrations and is expressed in micrometers
per day. Mineralization lag time (MLT) is expressed in
days. The percentage of double terramycin-labeled sur-
face of total trabecular surface (MS/BS) and bone for-
mation rate (BFR) completed the dynamic evaluation.
Static histomorphometric indices included ratios of tra-
becular bone volume and osteoid volume to bone volume
(BV/TV and OV/BV, respectively, expressed as per-
centages), as well as osteoid thickness (OTh), which is
expressed in micrometers. Percentage of total trabecu-
lar surface is used to express areas of eroded surface
(ES/BS), osteoid surface (OS/BS), osteoblast surface
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Table 1. Animal data
Initial body Final body Food intake Heart Heart weight/100 g Tail cuff
weight g weight g g/day weight g body weight plethysmyography mm Hg
PTx + Nx + LP 307.9 ± 11.8 416.9 ± 12.3 17.19 ± 0.54 1.31 ± 0.05 0.32 ± 0.01 141.6a ± 2.11
Sham + LP 310.3 ± 10.5 432.3 ± 13.0 17.59 ± 0.47 1.21 ± 0.03 0.28 ± 0.01 114.9 ± 1.20
PTx + Nx + HP 322.0 ± 10.0 352.3b ± 16.8 15.77c ± 0.38 1.25 ± 0.04 0.36b ± 0.01 137.5c ± 1.31
Sham + HP 311.1 ± 13.2 397.9 ± 8.8 17.53 ± 0.40 1.14 ± 0.03 0.29 ± 0.01 109.6 ± 1.13
Abbreviations are: PTx, parathyroidectomy; Nx, 5/6 nephrectomy; HP, high phosphorus, LP, low phosphorus.
aP < 0.05, PTx + Nx +LP vs. sham + HP and sham + LP; bP < 0.05, PTx + Nx + HP vs. all other groups; cP < 0.05, PTx +Nx + HP vs. sham + HP and sham + LP.
(ObS/BS) and osteoclast surface (OcS/BS). Trabecular
thickness (TbTh) and trabecular separation (TbSp) are
expressed in micrometers. Trabecular number (TbN)
is expressed per millimeter. Histomorphometric in-
dices are reported using nomenclature recommended by
the American Society of Bone and Mineral Research
(ASBMR) [12]. All animal data were obtained through
blind measurement.
Cardiovascular histology. Cross-sections of the heart,
thoracic aorta, and left femoral artery were embedded in
paraffin, sectioned at 4lm, and stained with hematoxylin-
eosin, Masson trichrome, von Kossa, Verhoeff, and Pi-
crosirius. A pathologist performed a blind qualitative
analysis looking for calcification or fibrosis.
Statistical analysis
Comparisons among the groups were made using one-
way analysis of variance (ANOVA) and Tukey post-hoc
test. Multivariate linear regression analysis was used to
determine which independent variables significantly in-
fluenced the dependent variable (heart weight/100 g body
weight, creatinine, and BV/TV). Independent variables
included in the multivariate analyses were those that had
proved to be significant in the univariate analysis. Graph
Pad Prism version 3.03 (GraphPad Software, Inc., San
Diego, CA, USA) and SPSS for Windows, version 8.0
(SPSS, Inc., Chicago, IL, USA) software programs were
used. Results are presented as mean ± SE. Values of P <
0.05 were considered statistically significant.
RESULTS
Body weight, food intake, TCP, and heart weight/100 g
body weight
Table 1 summarizes the animal data. The duration of
the uremia and diet treatment experiments was 52 days.
Initial body weight did not differ among the groups. At
the end of the study, despite the pair-feeding protocol,
PTx + Nx + HP rats had lower body weight. Compared
to those in all other groups, PTx + Nx + HP rats pre-
sented slightly lower food intake. Initial TCP readings
were similar among all groups. However, after 8 weeks
of uremia, rats that were submitted to Nx (PTx + Nx
+ LP and PTx + Nx + HP) developed hypertension, al-
though arterial pressure was comparable between the two
groups. Nonetheless, arterial pressure was significantly
lower in the two control groups. The heart weight was sim-
ilar among all groups. Heart weight normalized to body
weight was significantly higher in the PTx + Nx + HP
group than in any other group (Fig. 1).
Biochemical findings
Table 2 and Figure 2 show serum chemistries and hema-
tocrit results from uremic rats and from controls. The
continuous infusion of 1-34 rat PTH normalized serum
PTH levels in those animals previously submitted to PTx.
Sham animals who were fed an LP diet presented signifi-
cant lower serum PTH levels. Rats submitted to Nx (PTx
+ Nx + LP and PTx + Nx + HP) developed renal failure,
but those who were fed an HP diet (PTx + Nx + HP) had
higher serum creatinine levels than did PTx + Nx + LP
rats.
In PTx + Nx + HP rats, hematocrit levels were lower.
Animals who were submitted to Nx and fed an HP diet
(PTx + Nx + HP) presented very low iCa levels (hypocal-
cemia). In this group, considerable hyperphosphatemia
developed—evidenced by a pronounced elevation in cal-
cium × phosphorus (Ca × P) product—even in the pres-
ence of hypocalcemia.
Morphologic results
Bone histomorphometry parameters revealed that nor-
mal bone remodeling (bone turnover and bone architec-
ture) was not achieved in rats who were fed an HP diet
(PTx + Nx + HP and their controls, sham + HP) These
rats had lower bone volume and this effect was unrelated
to uremia. Higher trabecular separation and lower tra-
becular numbers were also detected in rats consuming
the HP diet (PTx + Nx + HP and their controls, sham
+ HP), denoting an osteoporosis effect of the HP diet.
Although not statistically significant, a higher MLT was
also observed in PTx + Nx + HP rats. Higher MARs were
seen in uremic rats fed an LP diet (PTx + Nx + LP) and
higher BFRs were seen in Nx animals (Table 3).
The efficacy of the HP diet in inducing cardiovascular
calcification and fibrosis was analyzed. Qualitative anal-
ysis involving myocardial and arterial histology detected
no vascular calcification or significant fibrosis.
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Fig. 1. Animal data for tail-cuff plethysmyo-
graphy (TCP), heart weight/body weight ra-
tio, serum creatinine (Cr), and bone trabec-
ular volume (BV/TV). (A) Animals submit-
ted to 5/6 nephrectomy (Nx) [high phospho-
rus (HP) or low phosphorus (LP)] had higher
TCP than sham animals. There were no dif-
ferences between parathyroidectomy (PTx)
+ Nx + HP and PTX + Nx + LP regard-
ing TCP. (B) Only PTx + Nx + HP animals
had a higher heart weight/body weight ratio
(HW/100 g BW), despite PTx + Nx + LP also
had higher blood pressure. (C) Animals that
were submitted to Nx had increased serum
creatinine levels, but those fed with a HP diet
had even higher than those fed with a LP diet.
(D) Animals that received a high content of
phosphorus on their diet had lower bone tra-
becular volume (BV/TV), and this was unre-
lated to uremia. #P < 0.05, PTx + Nx groups
vs. sham groups; ∗P < 0.05, PTx + Nx + HP
vs. all other groups;φP < 0.05, PTx +Nx + LP
vs. sham groups; P < 0.05, HP vs. LP groups.
Table 2. Biochemical data
Ionized calcium Phosphorus Calcium × phosphorus Creatinine Parathyoid
Hematocrit % mmol/L mg/dL mg2/dL2 mg/dL hormone pg/mL
PTx + Nx + LP 42.9 ± 1.1 1.19 ± 0.05 5.65 ± 0.48 52.09 ± 3.46 0.59a ± 0.03 114.9 ± 30.1
Sham + LP 42.9 ± 0.5 1.22 ± 0.05 4.43 ± 0.39 41.97 ± 1.73 0.32 ± 0.01 10.5b ± 2.8
PTx + Nx + HP 39.1c ± 1.3 0.61c ± 0.05 15.71c ± 2.56 67.79d ± 5.19 1.09c ± 0.15 86.8 ± 20.3
Sham+HP 43.5 ± 0.5 1.23 ± 0.07 4.95 ± 0.33 45.86 ± 2.46 0.46 ± 0.03 135.9 ± 28.6
Abbreviations are: PTx, parathyroidectomy; Nx, 5/6 nephrectomy; LP, low phosphorus; HP, high phosphorus.
aP < 0.05, PTx + Nx + LP vs. sham + HP and sham + LP; bP < 0.05, sham + LP vs. all other groups; cP < 0.05, PTx + Nx + HP vs. all other groups; dP < 0.05, PTx
+ Nx + HP vs. sham + HP and sham + LP.
Correlation analysis
Table 4 shows the results of the univariate analysis,
revealing that heart weight/100 g body weight correlated
positively and definitively with phosphorus levels (r =
0.76, P < 0.0001), Ca × P (r = 0.76, P < 0.0001), and
creatinine (r = 0.75 P < 0.0001). Strong correlations are
also shown between creatinine and phosphorus (r = 0.94,
P < 0.0001) and between creatinine and Ca × P (r =
0.81, P < 0.0001). Trabecular bone volume (BV/TV) was
correlated with serum calcium and with final body weight
and reached an almost significant degree of correlation
with serum phosphorus and with serum creatinine.
In Table 5, multivariate linear stepwise regression
results show that heart weight was dependent on phos-
phorus and TCP. Moreover, the correlation between
hematocrit and myocardial hypertrophy did not reach
the level of statistical significance (P = 0.059). Another
important result was that levels of creatinine were depen-
dent upon levels of phosphorus. TCP was also associated
with creatinine, but did not reach a significant result (P =
0.052). Trabecular bone volume (BV/TV) was dependent
on serum calcium and on serum phosphorus.
DISCUSSION
This study showed that, in rats with moderate renal fail-
ure that received an HP diet and physiologic PTH repo-
sition, there was no cardiovascular calcification, despite
the development of pronounced hyperphosphatemia and
elevated Ca × P. However, isolated hyperphosphatemia
was associated with the development of myocardial hy-
pertrophy. We also demonstrated that kidney dysfunc-
tion could be aggravated by hyperphosphatemia result-
ing from an HP diet. Another important finding is that
an HP diet was associated with the development of
an osteoporosis-like bone lesion that is aggravated by
uremia.
Until now, no experimental model of vascular calcifi-
cation in uremic rats has been established. We designed
this study in an attempt to demonstrate the develop-
ment of phosphorus-induced vascular calcification. In our
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Fig. 2. Animal data for serum parathor-
mone, ionized calcium, and phosphorus and
calcium × phosphorus product. (A) Sham an-
imals that received a low phosphorus (LP) diet
had lower serum parathyroid hormone (PTH)
levels. Animals submitted to 5/6 nephrectomy
(Nx) and parathyroidectomy (PTx) had sim-
ilar PTH levels, and allowed an evaluation
of isolated hyperphosphatemia. (B) PTx +
Nx + high phosphorus (HP) animals pre-
sented lower serum ionized calcium (iCa) lev-
els, higher serum phosphorus (P) levels (C)
and a higher calcium × phosphorus (Ca × P)
product (D). +P < 0.05, Ptx + Nx + LP vs. all
other groups; ∗P < 0.05, PTx + Nx + HP vs.
all other groups.
experimental study, we were unable to demonstrate the
relationship between hyperphosphatemia and vascular
calcification previously described in dialysis patients [2,
13]. There have been very few experimental studies eval-
uating vascular calcification in a uremic milieu. In one
of those studies (by Ejerblad, Erikson, and Johansson
[14]), in which uremia was induced in rats (with and with-
out PTx), arterial calcification was observed until sponta-
neous death or for 36 weeks. These authors showed that
the development of arterial changes was dependent upon
both the grade and the duration of uremia, since such
changes were found in only a few animals, who died im-
mediately upon becoming severely uremic. The authors
also pointed out that PTx largely prevented the devel-
opment of calcification, indicating that SHPT plays an
important role in the development of calcification. In our
study, due to the shorter observation period, we inten-
tionally induced only moderate renal failure in an attempt
to minimize the effect of anemia and acidosis.
In other studies not involving renal failure, vascular
calcification has been associated with hyperlipidemia and
with administration of nicotine, warfarin and high doses
of vitamin D, as well as with combinations of these fac-
tors [15]. The calcification observed could not be at-
tributed to phosphorus alone. Other important factors
are calcium content and the proportion of calcium to
phosphorus in the diet. These previous studies demon-
strated arterial calcification using diets with high calcium/
phosphorus proportions and high calcium contents, per-
haps favoring increased calcium levels (sometimes even
with hypercalcemia). In addition, the physiologic PTH
serum levels observed in our study could have been pro-
tective against calcification since it is suspected that high
PTH levels are a necessary condition for the development
of cardiovascular or even other soft tissue calcifications,
perhaps due to elevated cytosolic calcium [16]. In our
study, calcification was not detected, maybe because we
used rats, which developed hypocalcemia and moderate
renal failure, were treated only for 8 weeks and main-
tained normal levels of PTH. Perhaps the presence of
high PTH levels, more severe uremia and normocalcemia
or hypercalcemia is a necessary condition for arterial cal-
cification development in rats.
Otherwise, myocardial hypertrophy, as suggested by
the higher heart weight to body weight ratio, was evident
in the uremic hyperphosphatemic group (PTx + Nx +
HP). This hypertrophy was also unrelated to PTH lev-
els. A similar finding was described by Amann et al [17],
who found significantly higher left ventricular weights in
Nx rats fed an HP diet. However, the authors also found
PTH levels to be higher in this group, making it difficult
distinguish the role of phosphorus from that of PTH in
hypertrophy. Therefore, to our knowledge, this is the first
study to demonstrate that isolated hyperphosphatemia
is associated to myocardial hypertrophy. This could hap-
pen through a disproportionate rise in collagen content,
which would lead to myocardial fibrosis and structural re-
modeling of the hypertrophied myocardium. However,
we were unable to demonstrate myocardial fibrosis, al-
though a more sensitive analysis might. Nevertheless, this
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phosphorus-induced hypertrophy could be another fac-
tor contributing to high cardiovascular mortality in pa-
tients with CRF.
Many factors that may influence the progression of
renal failure have been identified, predominant among
which are glomerular and hemodynamic factors, systemic
hypertension, and high dietary levels of protein and phos-
phorus. Experimental evidence has been found that ex-
cess phosphorus plays a role in the progression of renal
failure in partially Nx rats [18]. However, these authors
did not employ a pair-feeding protocol and intake of di-
etary protein was not controlled. Therefore, some of the
beneficial effects may have been the result of protein re-
striction that accompanied the phosphorus restriction. In
addition, PTH probably differed between rats fed a HP
diet and those fed a LP diet. Other reports have docu-
mented the injurious effect of an HP diet on the kidney.
It is assumed that calcium phosphate deposition resulting
from hyperphosphatemia incites tissue injuries. However,
there have been no studies discounting the influence of
PTH on the pathogenesis of renal dysfunction. In this
study, we used physiologic doses to restore PTH to ap-
propriate levels and thereby demonstrated that kidney
dysfunction could be aggravated by HP diet alone. We
also found that, when dietary phosphorus was restricted
(even at constant PTH levels), kidney function was pro-
tected. The worsening of kidney function was apparently
unrelated to nephrocalcinosis, since we found only sparse
calcification in Nx animals (PTx + Nx + LP and PTx + Nx
+ HP, data not shown). It is probable that we were unable
to induce nephrocalcinosis due to the lower PTH levels
and to the fact that our rats were not fed a high calcium
diet. Cozzolino et al [19] analyzed the impact of different
phosphate binders on kidney tissue. The authors found
higher kidney calcium deposition in both untreated rats
(with high levels of phosphorus and PTH) and in calcium
salt–treated rats (with control of phosphorus and PTH
levels, but with a high calcium load). As in our study,
these authors were not able to identify vascular calcifica-
tion in their experimental model and suggested that Ca ×
P product-related induction of calcification is tissue-
specific and time-dependent.
Regarding bone effects of HP diets, we found lower tra-
becular bone volume in rats fed an HP diet. In addition, a
loss of connectivity, unrelated to uremia, was a significant
finding in such rats (PTx+Nx+HP and sham+HP). This
is the first study to address the role of dietary phospho-
rus and hyperphosphatemia in bone remodeling through
histomorphometry. Szabo´ [20] performed an experimen-
tal study that evaluated whether physiologic doses of ei-
ther PTH or calcitriol were able to normalize osteoclast
and osteoblast function in uremic rats. The authors found
that administration of PTH and calcitriol, in physiologic
doses that raised calcium serum levels, failed to normalize
the percentage of osteoclast surface. However, they were
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Table 4. Univariate analysis
Heart weight/100 g Tail-cuff Ionized
body weight plethysmyography Hematocrit Creatinine calcium Phosphorus Ca × P BV/TV
Final weight −0.67 0.45 −0.71 0.70 −0.74 −0.69 0.36
<0.001 <0.01 <0.0001 <0.0001 <0.0001 <0.001 <0.05
Heart weight/100 g body weight 0.56 −0.32 0.75 −0.76 0.76 0.76
<0.001 =0.07 <0.0001 <0.0001 <0.0001 <0.0001
Heart weight 0.41
<0.01
Food intake −0.43 0.63 −0.49 −0.48
<0.05 <0.0001 <0.001 <0.01
Tail-cuff plethysmyography 0.54 −0.39 0.43 0.56
<0.005 <0.05 <0.05 <0.001
Hematocrit −0.61 0.57 −0.67 −0.55
<0.001 <0.001 <0.0001 <0.01
Creatinine −0.84 0.94 0.81 −0.34
<0.0001 <0.0001 <0.0001 0.06
Ionized calcium −0.89 −0.76 0.52
<0.0001 <0.0001 <0.01
Phosphorus 0.88 −0.29
<0.0001 0.11
Table 5. Multivariate analysis of predictors of myocardial
hypertrophy, renal function, and trabecular bone volume
B Confidence index P value
Heart weight/100 g body weight
Hematocrit 0.004 0, 0.008 0.059
Tail-cuff plethysmyography 0.001 0.0008, 0.0012 0.03
Phosphorus 0.005 0.003, 0.007 0.00001
Creatine
Tail-cuff plethysmyography 0.003 −0.001, 0.005 0.052
Phosphorus 0.037 0.017, 0.057 0.002
BV/TV
Calcium 6.9 2.87, 10.93 0.002
Phosphorus 0.93 0.1, 1.72 0.03
BV/TV, trabecular bone volume to bone volume; B, standardized regression
coefficient (b).
unable to determine if the lack of responsiveness of the
bone cells at the surface was due to resistance to PTH,
calcitriol, both, or some other unidentified uremic factor.
In our study, dietary phosphorus probably played an im-
portant role in the pathogenesis of the bone lesion, even
in the absence of hypocalcemia, since animals that ate an
HP diet and had normal serum calcium levels (sham +
HP) also developed osteoporosis-like bone lesions. Bover
et al [21] also found that uremia and phosphorus each had
separate and major effects on skeletal resistance to PTH.
Our results show that restoration of PTH to appropriate
physiologic levels did not normalize bone remodeling.
This may be due to the fact that hyperphosphatemia de-
creases bone response to PTH, and that the HP diet was
also an important determinant of bone lesion. It is impor-
tant to note that adynamic bone lesions were not found.
Another factor that could be related to the lower trabec-
ular bone volume is undernourishment, since we found,
in the univariate analysis, a positive correlation between
BV/TV and final body weight.
CONCLUSION
We have demonstrated that isolated hyperphos-
phatemia was associated with myocardial hypertrophy,
worsening of renal function, and negative effects on bone
remodeling. Although no vascular calcification was ob-
served in this model, we cannot rule out an adverse effect
of hyperphosphatemia on the vascular (arterial) bed. Our
finding corroborates the importance of phosphorus con-
trol in reducing the morbidity and mortality described in
CRF patients. The molecular basis of the effect of hyper-
phosphatemia on target organs should be elucidated in
further studies.
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